Bristol Myers Squibb reported Phase 3 success for mezigdomide as an add-on to standard relapsed or refractory multiple myeloma therapy. In the Successor-2 study, the mezigdomide plus carfilzomib and dexamethasone regimen reduced the risk of progression or death by 52% versus carfilzomib and dexamethasone alone. At ASCO, BMS said median progression-free survival rose to 18 months with the mezigdomide combination compared with 8.3 months in the comparator arm. The company also highlighted higher response rates and more frequent deep responses, reinforcing the potential of mezigdomide as a successor approach to earlier cereblon modulator backbones. Mezigdomide is a cereblon E3 ligase modulator designed to degrade Ikaros (IKZF1) and Aiolos (IKZF3), a mechanism intended to drive apoptosis of myeloma cells. The company’s strategy now pivots to regulatory submissions and positioning versus expanding myeloma competition from cell therapies and bispecific antibodies.